DUBLIN--(BUSINESS WIRE)--May 14, 2019--

Bronchopulmonary Dysplasia - Pipeline Review, H1 2019 provides comprehensive information on the therapeutics under development for Bronchopulmonary Dysplasia (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bronchopulmonary Dysplasia (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Bronchopulmonary Dysplasia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 1, 1, 10 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bronchopulmonary Dysplasia (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Bronchopulmonary Dysplasia (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bronchopulmonary Dysplasia (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bronchopulmonary Dysplasia (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Bronchopulmonary Dysplasia (Respiratory).

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bronchopulmonary Dysplasia (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bronchopulmonary Dysplasia (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

  • Chiesi Farmaceutici SpA
  • Ethypharm SA
  • Insmed Inc
  • MediPost Co Ltd
  • Meridigen Biotech Co Ltd
  • Radikal Therapeutics Inc
  • Syntrix Biosystems Inc
  • Takeda Pharmaceutical Co Ltd
  • The Cell-Factory BVBA
  • Therabron Therapeutics Inc
  • United Therapeutics Corp

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/42szui

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Respiratory Drugs



SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 05/14/2019 06:23 AM/DISC: 05/14/2019 06:23 AM

Copyright Business Wire 2019.